PLRX Long Put Strategy
PLRX (Pliant Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
PLRX (Pliant Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $72.4M, a beta of 1.21 versus the broader market, a 52-week range of 1.09-1.95, average daily share volume of 537K, a public-listing history dating back to 2020, approximately 171 full-time employees. These structural characteristics shape how PLRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.21 places PLRX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long put on PLRX?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current PLRX snapshot
As of May 15, 2026, spot at $1.13, ATM IV 20.90%, IV rank 0.08%, expected move 5.99%. The long put on PLRX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long put structure on PLRX specifically: PLRX IV at 20.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a PLRX long put, with a market-implied 1-standard-deviation move of approximately 5.99% (roughly $0.07 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PLRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on PLRX should anchor to the underlying notional of $1.13 per share and to the trader's directional view on PLRX stock.
PLRX long put setup
The PLRX long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PLRX near $1.13, the first option leg uses a $1.13 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PLRX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PLRX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $1.13 | N/A |
PLRX long put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
PLRX long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on PLRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long put on PLRX
Long puts on PLRX hedge an existing long PLRX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying PLRX exposure being hedged.
PLRX thesis for this long put
The market-implied 1-standard-deviation range for PLRX extends from approximately $1.06 on the downside to $1.20 on the upside. A PLRX long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long PLRX position with one put per 100 shares held. Current PLRX IV rank near 0.08% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PLRX at 20.90%. As a Healthcare name, PLRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PLRX-specific events.
PLRX long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PLRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PLRX alongside the broader basket even when PLRX-specific fundamentals are unchanged. Long-premium structures like a long put on PLRX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current PLRX chain quotes before placing a trade.
Frequently asked questions
- What is a long put on PLRX?
- A long put on PLRX is the long put strategy applied to PLRX (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With PLRX stock trading near $1.13, the strikes shown on this page are snapped to the nearest listed PLRX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are PLRX long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the PLRX long put priced from the end-of-day chain at a 30-day expiry (ATM IV 20.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a PLRX long put?
- The breakeven for the PLRX long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PLRX market-implied 1-standard-deviation expected move is approximately 5.99%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on PLRX?
- Long puts on PLRX hedge an existing long PLRX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying PLRX exposure being hedged.
- How does current PLRX implied volatility affect this long put?
- PLRX ATM IV is at 20.90% with IV rank near 0.08%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.